Japan's pharmaceutical industry grew from postwar domestic antibiotic production, with Takeda, Astellas, Daiichi Sankyo, Eisai, and Chugai achieving global prominence. Until the 1990s it was a protected domestic market, but soaring drug development costs and global competition triggered a wave of major cross-border M&A from the 2000s. Takeda's $62 billion acquisition of Ireland's Shire in 2019 propelled it into the global top 10 by revenue. Chugai established a unique model through its strategic alliance with Roche, deploying proprietary antibody technology worldwide. In medical devices, Olympus commands a 70% global share in gastrointestinal endoscopes, while Terumo expands globally in cardiovascular devices. The transition to biologics, regenerative medicine, and digital therapeutics is the industry-wide challenge.
Founded in 1936. Diversified into amino acids, pharmaceuticals, and alcoholic beverages based on fermentation technology. Became a subsidiary of Kirin HD and divested alcohol and chemical businesses to concentrate on pharmaceuticals. Pursuing transformation into a Global Specialty Pharma centered on antibody drugs.
Founded in 1925. Grew through the detoxifying agent 'Guronsan,' then entered biopharmaceuticals in earnest by acquiring EPO manufacturing and sales rights. Strengthened R&D capabilities through a strategic alliance with Roche, and produced Japan's first domestically developed antibody drug 'Actemra.' A leading Japanese biopharmaceutical company.
Founded in 1919. Started as a microscope manufacturer, then entered medical devices through the invention of the gastrocamera. Gained widespread recognition with the hit camera 'Pen EE,' but underwent structural reform following an accounting fraud scandal. Concentrated on medical endoscopes and transformed into a global medical device company.
Founded in 1899. Known for 'Rohto Eye Drops,' the company acquired the global Mentholatum brand through the purchase of The Mentholatum Company. Expanding into skincare and health foods, and aggressively expanding into Southeast Asia, it evolved from an OTC drug maker into a comprehensive healthcare company.
Founded in 1781. Starting as a medicine wholesaler, Takeda produced blockbuster drugs including Alinamin, Leuprorelin, and Prograf. Through the Shire acquisition, Takeda entered the global top 10 and transformed into a global pharmaceutical company with rare diseases and plasma-derived therapies at its core.